Cytomegalovirus in Perilymphatic Fluid During Cochlear Implantation of Children Presenting a Sensorineural Hearing Loss

Trial Information
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
Summary

In France, children cochlear implantation (CI) is performed 400 times per year. Causes of profound sensorineural hearing loss (SNHL) are represented by congenital malformation of the inner ear for 50 to 60%. Most of the remaining cases of CI in children are caused by congenital CMV infection. The proportion of CMV inducing SNHL with a CI in children is not clearly defined. During CI, we aim to collect a very small sample of perilymphatic fluid and to analyse it with a CMV polymerised-chain-reaction to evaluate the involvement of CMV in SNHL.

Am I eligible for this trial?
Participation Requirements
Sex:
All
Maximum Age:
18
Healthy Volunteers:
No

• Children (under 18-year-old) presenting with a Sensorineural Hearing Loss with an indication of cochlear implantation

Where is this trial taking place?
Other Locations
France
Robert Debré Hospital
Recruiting
Paris
Who do I contact about this trial?
Primary
Natacha TEISSIER, MD PhD
natacha.teissier@aphp.fr
+331.40.03.53.67
Backup
Emilien CHEBIB, MD
emilienchebib@gmail.com
+336.68.66.46.87
When is this trial taking place?
Start Date: December 10, 2020
Estimated Completion Date: December 10, 2022
How many participants will be in this trial?
Target number of participants: 200
What treatment is being studied in this trial?
Experimental: collection of sample of perilymphatic fluid during cochlear implantation
collection of sample of perilymphatic fluid during cochlear implantation
What other conditions are being studied in this trial?

This content was sourced from clinicaltrials.gov